SCHEDULE 13G/A: Venrock Entities Disclose 4.9% Stake in Praxis Precision Medicines
Beneficial Ownership Report
A group of Venrock Healthcare Capital Partners entities and individuals have filed an amended Schedule 13G, disclosing a beneficial ownership of 4.9% in Praxis Precision Medicines, Inc. as of March 31, 2025.
Summary
- Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh (collectively, the "Reporting Persons") have filed an Amendment No. 4 to Schedule 13G.
- The filing pertains to their beneficial ownership of Common Stock, par value $0.0001 per share, of Praxis Precision Medicines, Inc.
- As of March 31, 2025, the Reporting Persons collectively beneficially own 1,016,497 shares of Praxis Precision Medicines, Inc. Common Stock.
- This aggregate amount represents 4.9% of the Issuer's outstanding Common Stock, based on 20,368,909 shares outstanding as of April 28, 2025, plus 26,512 shares issuable upon warrant exercise.
- The percentage was rounded down to 4.9% on the cover page due to EDGAR filing system limitations, with the precise beneficial ownership percentage being 4.98%.
- The Reporting Persons explicitly state that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: The document is a factual, routine regulatory filing (Schedule 13G) disclosing beneficial ownership. It contains no positive or negative operational or financial news, nor does it indicate any strategic intent to influence the issuer's control. Therefore, the sentiment is neutral.
Risks
- The beneficial ownership percentage of 4.98% was rounded down to 4.9% on the EDGAR filing system cover page due to field limitations, which could lead to a slight misperception of the exact stake.
Industry Context
This filing is a routine disclosure of a significant, but non-controlling, ownership stake by a venture capital firm in a publicly traded biotechnology company. Such filings are common as investment funds adjust their positions or as companies' outstanding share counts change, requiring updated disclosures.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional ownership stake, confirming that the stake is not held for the purpose of changing or influencing control of the issuer.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of event which requires the filing of this statement (beneficial ownership calculation date). |
| 04/28/2025 | Date as of which the Issuer's Definitive Proxy Statement on Schedule 14A reported 20,368,909 shares of Common Stock outstanding. |
| 05/15/2025 | Date the Schedule 13G Amendment No. 4 was signed and filed. |
Keywords
Praxis Precision Medicines, Venrock Healthcare Capital Partners, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.